Professor David Waugh is the Inaugural Pro-Vice Chancellor for Health and Medical Research and Engagement at University of South Australia, a role focused on developing inter-disciplinary and impactful research programmes that provide transformative solutions to inform improved patient outcomes and future healthcare practice. He was formerly the Head of School for Biomedical Sciences at Queensland University of Technology and prior to emigrating to Australia, he served as Director of the Patrick G Johnston Centre for Cancer Research at Queen’s University and the CRUK Belfast Cancer Centre, developing an ecosystem that integrated academic discovery science with entrepreneurial biotech research and development and finally... Read more
Home to the senior executive and facilitating communication between senior management, governing bodies and the University.
Professor David Waugh is the Inaugural Pro-Vice Chancellor for Health and Medical Research and Engagement at University of South Australia, a role focused on developing inter-disciplinary and impactful research programmes that provide transformative solutions to inform improved patient outcomes and future healthcare practice. He was formerly the Head of School for Biomedical Sciences at Queensland University of Technology and prior to emigrating to Australia, he served as Director of the Patrick G Johnston Centre for Cancer Research at Queen’s University and the CRUK Belfast Cancer Centre, developing an ecosystem that integrated academic discovery science with entrepreneurial biotech research and development and finally implementation in innovative early-phase clinical trials.
A Professor of Molecular Oncology and Therapeutics, David is an internationally-respected prostate cancer researcher focusing on using scientific discoveries to inform the use of new therapies in treating men with prostate cancer. He was the Founding Director of the FASTMAN Movember/PCUK Centre of Excellence (2013-2018) between Queen’s University Belfast and the University of Manchester in the UK, a programme delivering biomarkers and a series of translational studies to improve the outcomes of prostate cancer patients being treated for high-risk disease using radiotherapy protocols. His own research has focused on disrupting the inflammatory storms driven by chemokine signalling that underpin the aggressive and life-threatening behaviour of specific, genetically-defined subtypes of prostate cancer.
Doctor of Philosophy Creighton University
Excludes commercial-in-confidence projects.
Research outputs for the last seven years are shown below.
Open access indicates that an output is open access.
Armstrong, CW, Lyubomska, O, LaBonte, MJ & Waugh, DJ 2018, 'Protocols for studies on genetically engineered mouse models in prostate cancer', in Zoram Lulig (ed.), Prostate Cancer, Springer, US, ch. 11, pp. 195-206.
Bessot, A, Gunter, J, Waugh, D, Clements, JA, Hutmacher, DW, McGovern, J & Bock, N 2023, 'GelMA and biomimetic culture allow the engineering of mineralized, adipose, and tumor tissue human microenvironments for the study of advanced prostate cancer in vitro and in vivo', Advanced Healthcare Materials, online, pp. 1-18.
Amoroso, F, Glass, K, Singh, R, Liberal, F, Steele, RE, Maguire, S, Tarapore, R, Allen, JE, Van Schaeybroeck, S, Butterworth, KT, Prise, K, O'Sullivan, JM, Jain, S, Waugh, DJ & Mills, IG 2021, 'Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells', Scientific Reports, vol. 11, no. 1, article no. 4252, pp. 1-16.
Open access 7 7
Hanna, C, Dunne, VL, Walker, SM, Butterworth, KT, McCabe, N, Waugh, DJ, Kennedy, RD & Prise, KM 2021, 'ATM kinase inhibition preferentially sensitises pten-deficient prostate tumour cells to ionising radiation', Cancers, vol. 13, no. 1, article no. 79, pp. 1-17.
Open access 2 1
Murphy, RG, Roddy, AC, Srivastava, S, Baena, E, Waugh, DJ, O Sullivan, JM, McArt, DG, Jain, S & LaBonte, MJ 2020, 'Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods', NAR Genomics and Bioinformatics, vol. 2, no. 3, article no. lqaa062, pp. 1-7.
Di Mitri, D, Mirenda, M, Vasilevska, J, Calcinotto, A, Waugh, D & Alimonti, A and 19 other authors 2019, 'Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer', Cell Reports, vol. 28, no. 8, pp. 2156-2168.e5.
Open access 91 88
Gilmore, AR, Alderdice, M, Savage, K I, O Reilly, PG, Roddy, AC, Dunne, PD, Lawler, M, McDade, SS, Waugh, DJ & McArt, DG 2019, 'ACE: A workbench using evolutionary genetic algorithms for analyzing association in TCGA', Cancer Research, vol. 79, no. 8, pp. 2072-2075.
Jain, S, Lyons, C, Walker, S, McQuaid, S & Waugh, D 2018, 'Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy', Annals of Oncology, vol. 29, no. 1, pp. 215-222.
Open access 43 42
McCann, C, Crawford, N, Majkut, J, Holohan, C, Armstrong, CW, Maxwell, PJ, Ong, CW, LaBonte, MJ, McDade, SS, Waugh, DJ & Longley, DB 2018, 'Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists', Cell Death and Disease, vol. 9, no. 11, article no. 1081, pp. 1-13.
Open access 11 11
Ong, CW, Maxwell, P, Alvi, MA, McQuaid, S, Waugh, D, Mills, I & Salto Tellez, M 2018, 'A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases', Journal of Pathology: Clinical Research, vol. 4, no. 2, pp. 103-113.
Open access 16 16
Sumanasuriya, S, Omlin, A, Armstrong, A, Attard, G, Chi, KN, Bevan, CL, Shibakawa, A, IJzerman, MJ, De Laere, B, Lolkema, M, Lorente, D, Luo, J, Mehra, N, Olmos, D, Scher, H, Soule, H, Stoecklein, NH, Terstappen, LW, Waugh, D & de Bono, JS 2018, 'Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer', European Urology Oncology, vol. 1, no. 2, pp. 151-159.
Open access 23 22
Walker, SM, Knight, LA, McCavigan, AM, Logan, GE, Waugh, DJ & Kennedy, RD and 21 other authors 2017, 'Molecular subgroup of primary prostate cancer presenting with metastatic biology', European Urology.
Open access 21 18
Armstrong, CW, Maxwell, PJ, Ong, CW, Redmond, KM, McCann, C, Neisen, J, Ward, GA, Chessari, G, Johnson, C, Crawford, NT, LaBonte, MJ, Prise, KM, Robson, T, Salto Tellez, M, Longley, DB & Waugh, DJ 2016, 'PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy', Oncotarget, vol. 7, no. 7, pp. 7885-7898.
Open access 26 24
Bingham, V, Ong, CW, James, J, Maxwell, P, Waugh, D, Salto Tellez, M & McQuaid, S 2016, 'PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry', Human Pathology, vol. 47, no. 1, pp. 95-103.
Dunne, PD, McArt, DG, Bradley, CA, O'Reilly, PG, Barrett, HL, Cummins, R, O'Grady, T, Arthur, K, Loughrey, MB, Allen, WL, McDade, SS, Waugh, DJ, Hamilton, PW, Longley, DB, Kay, EW, Johnston, PG, Lawler, M, Salto Tellez, M & Van Schaeybroeck, S 2016, 'Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer', Clinical Cancer Research, vol. 22, no. 16, pp. 4095-4104.
Open access 104 95
McFarlane, S, Coulter, JA, Tibbits, P, O'Grady, A, McFarlane, C, Montgomery, N, Hill, A, McCarthy, HO, Young, LS, Kay, EW, Isacke, CM & Waugh, DJ 2015, 'CD44 increases the efficiency of distant metastasis of breast cancer', Oncotarget, vol. 6, no. 13, pp. 11465-11476.
Open access 72 67
McFarlane, S, McFarlane, C, Montgomery, N, Hill, A & Waugh, DJ 2015, 'CD44-mediated activation of α5β1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectin-enriched matrices', Oncotarget, vol. 6, no. 34, pp. 36762-36773.
Open access 39 38
Ong, CW, Chong, PY, McArt, DG, Chan, JY, Tan, HT, Kumar, AP, Chung, MC, Clement, MV, Soong, R, Van Schaeybroeck, S, Waugh, DJ, Johnston, PG, Dunne, PD & Salto Tellez, M 2015, 'The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers', Oncotarget, vol. 6, no. 14, pp. 12763-12773.
Open access 17
External engagement & recognition
|BC Cancer Agency||CANADA|
|Beaumont Hospital||UNITED STATES|
|Cantonal Hospital, St. Gallen||SWITZERLAND|
|Duke University||UNITED STATES|
|Erasmus MC Cancer Institute||NETHERLANDS|
|Heinrich-Heine University Medical Center||GERMANY|
|Imperial College of Science, Technology and Medicine||UNITED KINGDOM|
|Institute of Cancer Research||UNITED KINGDOM|
|Istituti di Ricovero e Cura a Carattere Scientifico||ITALY|
|Johns Hopkins University||UNITED STATES|
|Memorial Sloan Kettering Cancer Centre||UNITED STATES|
|National Cancer Centre Singapore||SINGAPORE|
|National University of Singapore||SINGAPORE|
|Oncoceutics (United States)||UNITED STATES|
|Prostate Cancer Foundation||UNITED STATES|
|Queen's University Belfast||UNITED KINGDOM|
|Queensland University of Technology||AUSTRALIA|
|Radboud University Nijmegen Medical Centre||NETHERLANDS|
|Royal Marsden Hospital||UNITED KINGDOM|
|Spanish National Cancer Research Centre||SPAIN|
|University of Antwerp||BELGIUM|
|University of Manchester||UNITED KINGDOM|
|University of Oxford||UNITED KINGDOM|
|University of Padua||ITALY|
|University of Twente||NETHERLANDS|